News | January 31, 2026
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
Winlevi is authorized in EU for the treatment of acne vulgaris
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The company has received approval from DCGI to begin patient enrolment and dosing in the country
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Subscribe To Our Newsletter & Stay Updated
